GlassScriptPhysician profile
Corah J Senik
NPI 1417156134
$2,747.27
in general payments reported to CMS, 2019-2025
24 companies · $827 in 2025
The $827 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.56 · 2022: $609 · 2023: $632 · 2024: $653 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $445.90 | 2021-2025 | |
| Abbvie INC. | $333.69 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $310.04 | 2022-2025 | Ilumya |
| Janssen Biotech, INC. | $279.70 | 2021-2025 | Tremfya |
| Genzyme Corporation | $214.35 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.90 | 2022-2025 | Sotyktu |
| Organon LLC | $139.53 | 2023-2025 | Vtama, Hadlima, Nexplanon |
| Amgen INC. | $130.16 | 2022-2025 | Otezla, Otezla |
| Fresenius Kabi USA, LLC | $89.47 | 2023-2024 | Idacio |
| Biofrontera INC. | $72.86 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $72.72 | 2022-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $62.55 | 2022-2024 | Dupixent |
| Incyte Corporation | $56.12 | 2022-2025 | Opzelura |
| Pfizer INC. | $48.12 | 2022-2024 | |
| Leo Pharma INC. | $45.66 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.31 | 2022-2023 | Siliq |
| Mayne Pharma Commercial LLC | $40.65 | 2022-2023 | |
| Lilly USA, LLC | $37.06 | 2022-2025 | Ebglyss, Taltz |
| Genentech USA, INC. | $32.90 | 2022 | |
| Arcutis Biotherapeutics, INC. | $31.85 | 2023-2024 | Zoryve |
| Botanix Sb INC | $21.33 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.92 | 2023 | Cyltezo |
| Dermavant Sciences, INC. | $16.95 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $14.53 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corah Senik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.